Loading
A phase 1/2 trial of capecitabine and pembrolizumab in triple-negative breast cancer, run by Dartmouth-Hitchcock Medical Center, now recruiting.
A Study of Tetrathiomolybdate (TM) Plus Capecitabine is a phase 1/2, randomised interventional study registered as NCT06134375 by Dartmouth-Hitchcock Medical Center, with a registry enrolment figure of 204 participants, started 2024-11-26 and due to reach its primary completion in 2031-06-26. Interventions recorded: Tetrathiomolybdate; Capecitabine; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer; Residual Disease. Triple-negative eligibility wording from the registry: "Patients must have histologically confirmed breast malignancy that is Triple negative tumors as defined as ER and PR \<1% and HER2 negative as per ASCO/CAP guidelines". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Capecitabine, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.